FDA Approves Merck’s ZERBAXA® (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

40

KENILWORTH, N.J.–(BUSINESS WIRE)–<a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank">$MRK</a> <a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank">#MRK</a>–FDA Approves Merck’s ZERBAXA 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia http://www.businesswire.com/news/home/20190603005822/en/FDA-Approves-Merck%E2%80%99s-ZERBAXA%C2%AE-ceftolozane-tazobactam-3g/?feedref=JjAwJuNHiystnCoBq_hl-WFAllVCLJFCqzlmaJ8DKHU4plfPZtlGYRDUHCSmgbii6XkLWuQZD-HgGRnjQvCyg3iCfEFIaJW7-otp9V1XQiK2eHTJy3ZqOEt7kKgLu20J